You are here

Calcium channel blocker use is associated with lower fasting serum glucose among adults with diabetes from the REGARDS study.

TitleCalcium channel blocker use is associated with lower fasting serum glucose among adults with diabetes from the REGARDS study.
Publication TypeJournal Article
Year of Publication2016
AuthorsKhodneva, Y, Shalev, A, Frank, SJ, Carson, AP, Safford, MM
JournalDiabetes Res Clin Pract
Volume115
Pagination115-21
Date Published2016 May
ISSN1872-8227
KeywordsAdult, Aged, Biomarkers, Blood Glucose, Calcium Channel Blockers, Diabetes Mellitus, Dose-Response Relationship, Drug, Fasting, Female, Humans, Insulin, Male, Middle Aged, Prognosis, Risk Factors, Stroke, Survival Rate, United States, Verapamil
Abstract

BACKGROUND: Ca(2+) channel blockers (CCB) and verapamil in particular prevented β-cell apoptosis and enhanced endogenous insulin levels in recent studies of mouse models of diabetes. Verapamil's effect on serum glucose levels in humans with diabetes is not described.METHODS: We used data from the REasons for Geographic and Racial Differences in Stroke (REGARDS), a national cohort study of community-dwelling middle-aged and older adults, enrolled between 2003 and 2007 from the continental United States. We examined associations of CCB and verapamil use with fasting serum glucose among 4978 adults with diabetes, controlling for covariates in generalized linear models (GLM).FINDINGS: The sample included 1484 (29.6%) CCB users, of which 174 (3.4%) were verapamil users. In fully adjusted GLMs, CCB users had 5mg/dL lower serum glucose compared to non-users. Verapamil users had on average 10mg/dL lower serum glucose compared to CCB non-users with substantially greater differences among insulin users: 24mg/dL lower serum glucose among users of insulin in combination with oral agents and 37mg/dL lower among users of insulin alone.INTERPRETATION: CCB and in particular verapamil use was associated with lower fasting blood glucose levels among REGARDS participants with diabetes.FUNDING: UO1NS041588 from the National Institute of Neurological Disorders and Stroke, NIH; K24HL111154 and R01HL080477 from the National Heart, Lung, and Blood Institute.

DOI10.1016/j.diabres.2016.01.021
Alternate JournalDiabetes Res. Clin. Pract.
PubMed ID26818894
PubMed Central IDPMC4887408
Grant ListK24 HL111154 / HL / NHLBI NIH HHS / United States
P30 DK079626 / DK / NIDDK NIH HHS / United States
R01 DK078752 / DK / NIDDK NIH HHS / United States
UC4 DK104204 / DK / NIDDK NIH HHS / United States
U01 NS041588 / NS / NINDS NIH HHS / United States
R01 HL080477 / HL / NHLBI NIH HHS / United States
K01 DK095928 / DK / NIDDK NIH HHS / United States